DermBiont lands $28m Series A2

DermBiont, a developer of targeted topical therapeutics that address the root causes of skin diseases, has raised $28 million in Series A2 financing.

21 December 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles